1-20 of 12639 Search Results for

cyclins

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 3891.
Published: 15 June 2022
... million and a survival rate less than 50%. Due to significant side effects and ineffectiveness of standard chemotherapy for relapse refractory disease, the treatment options are now shifting towards targeted therapies. Cyclin-dependent kinases (CDKs) are potential cancer therapeutic targets because...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): CT191.
Published: 15 June 2022
... adverse event; TEAE, treatment-emergent adverse event. Citation Format: Nicholas J. Vogelzang, Ben George, Nissa Ashenbramer, William J. Edenfield, Donald Richards, Mitchell E. Gross, Gil D. Fine, Pablo Martinez. Phase 1, first-in-human, dose-escalation study of oral TP-1287, a cyclin dependent...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 327.
Published: 15 June 2022
...-positive gastric/gastroesophageal junction (GEJ) cancers. Amplification of CCNE1, which encodes cyclin E, has been proposed as a mechanism of resistance to HER2-targeted therapies. The Wee1 kinase inhibitor adavosertib (AZD1775) has demonstrated enhanced antitumor activity in the setting of cyclin E...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 5379.
Published: 15 June 2022
...Pablo D. Garcia; Catherine E. Gleason; Miles Membreno; Frances Hamkins-Indik; Gavin Situ; Bernard Levin; Evelyn W. Wang; Siegfried Leung; Breena Fraga; Andrew Bockus; James Aggen; David Spellmeyer; David J. Earp; Rajinder Singh Inhibition of substrate binding to Cyclin A has been postulated...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 2318.
Published: 15 June 2022
... compounds targeting CDK8/Cyclin C with high potency in low nanomolar range have been reported. These compounds differ with respect to their binding modes, but all of them show high potency in biochemical assays, inhibition of tumor cell growth, and for many in vivo activities in different tumor cell...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 1622.
Published: 15 June 2022
...Victor Chalfant; Carlos Riveros; Sanjeev Shukla; Teruko Osumi; K Balaji Cyclin-dependent kinase 12 (CDK12) belongs to the cyclin-dependent kinase (CDK) family of serine/threonine protein kinases. In contrast to CDKs which promote cell cycle progression, CDK12 is a transcriptional regulator...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 816.
Published: 15 June 2022
...Kathy Q. Cai; Sara E. Hanley; Andres Klein-Szanto; Kerry S. Campbell; Randy Strich Cyclin c is a component of the Cdk8 kinase module that plays both a positive and negative role in transcription. In addition, cellular damage induces cyclin c re-localization to the mitochondria where it stimulates...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 5471.
Published: 15 June 2022
...; Giuseppina M. Carbone; Carlo V. Catapano CDK9 is a serine/threonine kinase belonging to the subclass of the transcription associated CDKs. CDK9 complexes with cyclin T and cyclin K, the positive transcription elongation factor b (P-TEFb), and phosphorylates Serine 2 of RNA polymerase II (pSer2 RNAPII...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 2304.
Published: 15 June 2022
...Daniel Müller; Frank Totzke; Thomas Weber; Andreas Gericke; Diane Krämer; Carolin Heidemann-Dinger; Constance Ketterer; Michael H. Kubbutat The family of human Cyclin dependent kinases (CDKs) comprises 20 different CDKs that play critical roles in the regulation of cell cycle progression, gene...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 2592.
Published: 15 June 2022
...Said Akli; Amriti R. Lulla; Francisco R. Saenz; Fuchenchu Wang; Natalie W. Fowlkes; Tuyen Bui; Yan Wang; Sofia Mastoraki; Min Jin Ha; Kelly K. Hunt; Khandan Keyomarsi Background: Cyclin E, a key mediator for G1 to S transition, has unique tumor-specific deregulation in multiple malignancies...
Journal Articles
Cancer Res (2022) 82 (10): 1937–1952.
Published: 16 May 2022
...) to transcriptionally activate cyclin D1 (CCND1) expression via co-occupation of its promoter and superenhancer elements. DHX37 and PLRG1 promoted liver cancer cell proliferation and contributed to the poor prognosis of patients with HCC. Importantly, CCND1 inhibitors were effective as antiproliferative agents...
Includes: Supplementary data
Journal Articles
Cancer Res (2022) 82 (7): 1170–1171.
Published: 01 April 2022
...David A. Frank Cyclin-dependent kinases (CDK), such as CDK4 and CDK6, phosphorylate RB1 to release the transcription factor E2F and drive the transition from G1 to S-phase of the cell cycle. Inhibitors of these kinases thereby block cell-cycle progression and presumably exert...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 5648.
Published: 15 June 2022
... months of palbociclib exposure: one with biallelic genomic RB1 inactivation and the other with the first known example of a cyclin D1 coding sequence fusion with oncogenic properties (CCND1::chr11.g:70025223). The CCND1 fusion deleted the cyclin D1 C-terminal Thr286 and Thr288 residues which mediate...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 5373.
Published: 15 June 2022
... in PDXs detected by tissue microarray. As Cyclin D1 plays a critical role in G1/S transition in cell cycle progression, proteins regulating G1 phase were profiled in ESCC cells. Elevated expression of Cyclin D1, p21 and Rb was found in CYH33-sensitive cells compared to those in resistant cells, indicating...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 2306.
Published: 15 June 2022
...Victoria Brown; Phil Ramsden; Nealia House; Richard Vargas; Jian Guo; Ruduan Wang; Riadh Lobbardi; Maxine Chen; Douglas Wilson; Joseph Kim; Neil Bifulco; Michelle Maynard; Emanuele Perola; Dean Zhang; Steve Wenglowsky; Yoon Jong Choi Background: Cyclin-dependent kinases (CDK) are a class of enzymes...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 2221.
Published: 15 June 2022
... excision margin using multiple methods including routine histopathological assessment, FISH (CCND1 amplification), and multiplex immunofluorescence (mIF: SOX10, p16, Cyclin D1 and PRAME) in primary acral melanomas with initially histopathologically reported clear excision margins of >0.3mm (n=85...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 4067.
Published: 15 June 2022
... antagonistic drug effects). To better understand molecular mechanisms underlying the observed synergistic effect in t(11;14), we performed western blot analysis in these cell lines treated with selinexor, venetoclax, the combination, or DMSO control for 24 hours. We measured protein levels of Cyclin D1, which...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 2568.
Published: 15 June 2022
...jiaqi Liang; Dai Cheng; Yali Guo; xiaobin zhang; Xipan Liu; Jia Fu; Qiang Ding; Wen Xiong; Fang Li; Yaoyu Chen; Qing Sheng Cyclin E1 amplification is prevalent in cancers with high unmet medical need such as high grade serous ovarian cancer, stomach cancer and esophageal cancer. Cancer cell lines...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 2573.
Published: 15 June 2022
... mutations, PTEN loss, or receptor tyrosine kinase activation. In HPV-negative tumors, CDKN2A (p16) inactivation or CCND1 (cyclin D1) amplification frequently occurs resulting in sustained cyclin dependent kinase (CDK) 4/6 activation. The aim of our study was to investigate the efficacy of PI3K/AKT/mTOR...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 3955.
Published: 15 June 2022
... (BTKi) is a novel and fast growing medical challenge in treating patients with mantle cell lymphoma (MCL). Thus, developing a novel therapy to overcome this BTKi-CAR T dual resistance (Dual-R) is an urgent need. Our unpublished data revealed MYC targets and cyclin-dependent kinase 9 (CDK9) are highly...